Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

AbbVie Announces VRAYLAR Receives Reimbursement Recommendation From Canada's Drug Agency For Treatment Of Schizophrenia In Adults Following Successful Negotiations And LOI

Author: Benzinga Newsdesk | September 04, 2024 08:02am
  • VRAYLAR, an atypical antipsychotic medication, received its Notice of Compliance from Health Canada on April 22, 2022.
  • Following the positive recommendation from INESSS issued in October 2022, VRAYLAR completed negotiations at pCPA and has an active letter of intent (LOI). Québec and the federal plans (NIHB, CSC and VAC) have subsequently listed VRAYLAR, for the treatment of schizophrenia, as a result of this completed negotiation and LOI.

Posted In: ABBV


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist